Top

Immunity & Ageing

Published in:

Open Access 01-12-2022 | Dementia | Research

High sensitivity C-reactive protein and glycated hemoglobin levels as dominant predictors of all-cause dementia: a nationwide population-based cohort study

Authors: Yen-Chun Fan, Chia-Chi Chou, Bagas Suryo Bintoro, Kuo-Liong Chien, Chyi-Huey Bai

Published in: Immunity & Ageing | Issue 1/2022

Abstract

Background

Chronic inflammation might play a major role in the pathogenesis linking diabetes mellitus (DM) to cognition. In addition, DM might be the main driver of dementia risk. The purpose of the present study was to evaluate whether inflammation, glycation, or both are associated with the risk of developing all-cause dementia (ACD).

Methods

A nationwide population-based cohort study was conducted with 4113 participants. The data were obtained from the Taiwanese Survey on Prevalence of Hypertension, Hyperglycemia, and Hyperlipidemia (TwSHHH) in 2007, which was linked with the Taiwan National Health Insurance Research Database (NHIRD). The markers of inflammation, expressed as hs-CRP, and glycation, presented as HbA1c, were measured. High levels of hs-CRP and HbA1c were defined as values greater than or equal to the 66th percentile. Developed ACD was identified based on the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes.

Results

During 32,926.90 person-years, 106 individuals developed ACD in up to 8 years of follow-up. The study participants were separated into four categories by the top tertiles of hs-CRP and HbA1c based on the 66th percentile: high levels of both hs-CRP and HbA1c, only high levels of hs-CRP, only high levels of HbA1c, and non-high levels of hs-CRP nor HbA1c. Those who with a high level of only hs-CRP had the higher hazard for developing ACD (adjusted HR = 2.58; 95% CI = 1.29 ~ 5.17; P = 0.007), followed by the group with a high level of only HbA1c (adjusted HR = 2.52; 95% CI = 1.34 ~ 4.74; P = 0.004) and the group with high levels of both hs-CRP and HbA1c (adjusted HR = 2.36; 95% CI = 1.20 ~ 4.62; P = 0.012). Among those aged less than 65 years, hs-CRP was the only significant predictor of ACD risk (P = 0.046), whereas it did not yield any significant result in the elderly.

Conclusions

A higher risk of developing ACD was found not only in patients with high levels of inflammation but also high levels of glycated hemoglobin. Future studies should focus on the clinical implementation of hs-CRP or HbA1c to monitor cognitive deficits.

Talwar P, Grover S, Sinha J, Chandna P, Agarwal R, Kushwaha S, et al. Multifactorial analysis of a biomarker pool for Alzheimer disease risk in a north Indian population. Dement Geriatr Cogn Disord. 2017;44(1–2):25–34. https://doi.org/10.1159/000477206.CrossRefPubMed

Liu Y, Zhang S, Tomata Y, Nurrika D, Sugawara Y, Tsuji I. The impact of risk factors for dementia in China. Age Ageing. 2020;49(5):850–5. https://doi.org/10.1093/ageing/afaa048.CrossRefPubMed

Deckers K, van Boxtel MP, Schiepers OJ, de Vugt M, Muñoz Sánchez JL, Anstey KJ, et al. Target risk factors for dementia prevention: a systematic review and Delphi consensus study on the evidence from observational studies. Int J Geriatr Psychiatry. 2015;30(3):234–46. https://doi.org/10.1002/gps.4245.CrossRefPubMed

Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia prevention, intervention, and care: 2020 report of the lancet commission. Lancet. 2020;396(10248):413–46. https://doi.org/10.1016/s0140-6736(20)30367-6.CrossRefPubMedPubMedCentral

Dhana K, Evans DA, Rajan KB, Bennett DA, Morris MC. Healthy lifestyle and the risk of Alzheimer dementia: findings from 2 longitudinal studies. Neurology. 2020;95(4):e374–e83. https://doi.org/10.1212/wnl.0000000000009816.CrossRefPubMedPubMedCentral

Sharma N, Singh AN. Exploring biomarkers for alzheimer's disease. J Clin Diagn Res. 2016;10(7):Ke01–6. https://doi.org/10.7860/jcdr/2016/18828.8166.CrossRefPubMedPubMedCentral

Mushtaq G, Khan JA, Kumosani TA, Kamal MA. Alzheimer's disease and type 2 diabetes via chronic inflammatory mechanisms. Saudi J Biol Sci. 2015;22(1):4–13. https://doi.org/10.1016/j.sjbs.2014.05.003.CrossRefPubMed

Anjum I, Fayyaz M, Wajid A, Sohail W, Ali A. Does obesity increase the risk of dementia: a literature review. Cureus. 2018;10(5):e2660. https://doi.org/10.7759/cureus.2660.CrossRefPubMedPubMedCentral

Straub RH. The brain and immune system prompt energy shortage in chronic inflammation and ageing. Nat Rev Rheumatol. 2017;13(12):743–51. https://doi.org/10.1038/nrrheum.2017.172.CrossRefPubMed

10.

Liu Y, Li H, Wang J, Xue Q, Yang X, Kang Y, et al. Association of cigarette smoking with cerebrospinal fluid biomarkers of neurodegeneration, neuroinflammation, and oxidation. JAMA Netw Open. 2020;3(10):e2018777. https://doi.org/10.1001/jamanetworkopen.2020.18777.CrossRefPubMedPubMedCentral

11.

Hayley S, Hakim AM, Albert PR. Depression, dementia and immune dysregulation. Brain: J Neurol. 2021;144(3):746–60. https://doi.org/10.1093/brain/awaa405.CrossRef

12.

Toppala S, Ekblad LL, Tuisku J, Helin S, Johansson JJ, Laine H, et al. Association of Early β-amyloid accumulation and Neuroinflammation measured with [(11) C]PBR28 in elderly individuals without dementia. Neurology. 2021;96(12):e1608–e19. https://doi.org/10.1212/wnl.0000000000011612.CrossRefPubMedPubMedCentral

13.

Fan YC, Hsu JL, Tung HY, Chou CC, Bai CH. Increased dementia risk predominantly in diabetes mellitus rather than in hypertension or hyperlipidemia: a population-based cohort study. Alzheimers Res Ther. 2017;9(1):7. https://doi.org/10.1186/s13195-017-0236-z.CrossRefPubMedPubMedCentral

14.

Saha S, Schwarz PE. Impact of glycated hemoglobin (HbA1c) on identifying insulin resistance among apparently healthy individuals. J Public Health. 2017;25(5):505–12. https://doi.org/10.1007/s10389-017-0805-4.CrossRef

15.

Marden JR, Mayeda ER, Tchetgen Tchetgen EJ, Kawachi I, Glymour MM. High hemoglobin A1c and diabetes predict memory decline in the health and retirement study. Alzheimer Dis Assoc Disord. 2017;31(1):48–54. https://doi.org/10.1097/wad.0000000000000182.CrossRefPubMedPubMedCentral

16.

Umeno A, Yoshida Y. Utility of hemoglobin A1c in detecting risk of type 2 diabetes: comparison of hemoglobin A1c with other biomarkers. J Clin Biochem Nutr. 2019;65(1):59–64. https://doi.org/10.3164/jcbn.19-16.CrossRefPubMedPubMedCentral

17.

Hobday AL, Parmar MS. The link between diabetes mellitus and tau hyperphosphorylation: implications for risk of Alzheimer's disease. Cureus. 2021;13(9):e18362. https://doi.org/10.7759/cureus.18362.CrossRefPubMedPubMedCentral

18.

Vinuesa A, Pomilio C, Gregosa A, Bentivegna M, Presa J, Bellotto M, et al. Inflammation and insulin resistance as risk factors and potential therapeutic targets for Alzheimer's disease. Front Neurosci. 2021;15:653651. https://doi.org/10.3389/fnins.2021.653651.CrossRefPubMedPubMedCentral

19.

Bednarz K, Siuda J. Alzheimer's disease and type 2 diabetes mellitus: similarities in pathomechanisms lead to therapeutic opportunities. Neurol Neurochir Pol. 2021;55(5):418–28. https://doi.org/10.5603/PJNNS.a2021.0056.CrossRefPubMed

20.

Ahmed M, Islam MM, Rahman MA, Rubaiyat KA, Khuda CKE, Ferdous KAF, et al. Association of C-reactive protein and HbA1c in the severity of coronary artery disease in patients with ischemic heart disease. Cardiovasc J. 2018;11(1):53–8. https://doi.org/10.3329/cardio.v11i1.38243.CrossRef

21.

Schillinger M, Exner M, Amighi J, Mlekusch W, Sabeti S, Rumpold H, et al. Joint effects of C-reactive protein and glycated hemoglobin in predicting future cardiovascular events of patients with advanced atherosclerosis. Circulation. 2003;108(19):2323–8. https://doi.org/10.1161/01.CIR.0000095267.24234.00.CrossRefPubMed

22.

Sander D, Schulze-Horn C, Bickel H, Gnahn H, Bartels E, Conrad B. Combined effects of hemoglobin A1c and C-reactive protein on the progression of subclinical carotid atherosclerosis: the INVADE study. Stroke. 2006;37(2):351–7. https://doi.org/10.1161/01.STR.0000199034.26345.bc.CrossRefPubMed

23.

Alfaddagh A, Martin SS, Leucker TM, Michos ED, Blaha MJ, Lowenstein CJ, et al. Inflammation and cardiovascular disease: from mechanisms to therapeutics. Am J Prevent Cardiol. 2020;4:100130. https://doi.org/10.1016/j.ajpc.2020.100130.CrossRef

24.

Prasad K. Does HbA1cc play a role in the development of cardiovascular diseases? Curr Pharm Des. 2018;24(24):2876–82. https://doi.org/10.2174/1381612824666180903121957.CrossRefPubMed

25.

Hsieh C-Y, Su C-C, Shao S-C, Sung S-F, Lin S-J, Yang Y-HK, et al. Taiwan’s National Health Insurance Research Database: past and future. Clin Epidemiol. 2019;11:349–58. https://doi.org/10.2147/CLEP.S196293.CrossRefPubMedPubMedCentral

26.

Fan YC, Chou CC, You SL, Sun CA, Chen CJ, Bai CH. Impact of worsened metabolic syndrome on the risk of dementia: a nationwide cohort study. J Am Heart Assoc. 2017;6(9):e004749. https://doi.org/10.1161/jaha.116.004749.CrossRefPubMedPubMedCentral

27.

Gabin JM, Saltvedt I, Tambs K, Holmen J. The association of high sensitivity C-reactive protein and incident Alzheimer disease in patients 60 years and older: the HUNT study. Norway Immun Ageing. 2018;15(1):4. https://doi.org/10.1186/s12979-017-0106-3.CrossRefPubMed

28.

Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia aging study. Ann Neurol. 2002;52(2):168–74. https://doi.org/10.1002/ana.10265.CrossRefPubMed

29.

Noble JM, Manly JJ, Schupf N, Tang MX, Mayeux R, Luchsinger JA. Association of C-reactive protein with cognitive impairment. Arch Neurol. 2010;67(1):87–92. https://doi.org/10.1001/archneurol.2009.308.CrossRefPubMedPubMedCentral

30.

Yaffe K, Blackwell T, Whitmer RA, Krueger K, Barrett CE. Glycosylated hemoglobin level and development of mild cognitive impairment or dementia in older women. J Nutr Health Aging. 2006;10(4):293–5.PubMed

31.

Wium-Andersen IK, Rungby J, Jørgensen MB, Sandbæk A, Osler M, Wium-Andersen MK. Risk of dementia and cognitive dysfunction in individuals with diabetes or elevated blood glucose. Epidemiol Psychiatr Sci. 2019;29:e43. https://doi.org/10.1017/s2045796019000374.CrossRefPubMedPubMedCentral

32.

Ramirez A, Wolfsgruber S, Lange C, Kaduszkiewicz H, Weyerer S, Werle J, et al. Elevated HbA1c is associated with increased risk of incident dementia in primary care patients. J Alzheimers Dis. 2015;44(4):1203–12. https://doi.org/10.3233/jad-141521.CrossRefPubMed

33.

Ahmadi-Abhari S, Kaptoge S, Luben RN, Wareham NJ, Khaw KT. Longitudinal association of C-reactive protein and Haemoglobin A1c over 13 years: the European prospective investigation into Cancer--Norfolk study. Cardiovasc Diabetol. 2015;14(1):61. https://doi.org/10.1186/s12933-015-0224-1.CrossRefPubMedPubMedCentral

34.

Markus HS, Hunt B, Palmer K, Enzinger C, Schmidt H, Schmidt R. Markers of endothelial and hemostatic activation and progression of cerebral white matter hyperintensities: longitudinal results of the Austrian stroke prevention study. Stroke. 2005;36(7):1410–4. https://doi.org/10.1161/01.STR.0000169924.60783.d4.CrossRefPubMed

35.

Torimoto K, Okada Y, Mori H, Tanaka Y. Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus. Cardiovasc Diabetol. 2013;12(1):1. https://doi.org/10.1186/1475-2840-12-1.CrossRefPubMedPubMedCentral

36.

Tamura Y, Kimbara Y, Yamaoka T, Sato K, Tsuboi Y, Kodera R, et al. White matter Hyperintensity in elderly patients with diabetes mellitus is associated with cognitive impairment, functional disability, and a high Glycoalbumin/Glycohemoglobin ratio. Front Aging Neurosci. 2017;9:220. https://doi.org/10.3389/fnagi.2017.00220.CrossRefPubMedPubMedCentral

37.

Low A, Mak E, Malpetti M, Passamonti L, Nicastro N, Stefaniak JD, et al. In vivo neuroinflammation and cerebral small vessel disease in mild cognitive impairment and Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2020;92(1):45–52. https://doi.org/10.1136/jnnp-2020-323894.CrossRef

38.

Johnson NF, Gold BT, Brown CA, Anggelis EF, Bailey AL, Clasey JL, et al. Endothelial function is associated with White matter microstructure and executive function in older adults. Front Aging Neurosci. 2017;9:255. https://doi.org/10.3389/fnagi.2017.00255.CrossRefPubMedPubMedCentral

39.

Yan Y, Li S, Liu Y, Bazzano L, He J, Mi J, et al. Temporal relationship between inflammation and insulin resistance and their joint effect on hyperglycemia: the Bogalusa heart study. Cardiovasc Diabetol. 2019;18(1):109. https://doi.org/10.1186/s12933-019-0913-2.CrossRefPubMedPubMedCentral

40.

Bahrami A, Zarghami N, Khajehali L. Association between C-reactive protein and HbA1C among patients with type 2 diabetes mellitus. Iran J Diabetes Lipid Disord. 2007;6(3):59–65.E32.

41.

Seo YH, Shin HY. Relationship between hs-CRP and HbA1c in diabetes mellitus patients: 2015-2017 Korean National Health and nutrition examination survey. Chonnam Med J. 2021;57(1):62–7. https://doi.org/10.4068/cmj.2021.57.1.62.CrossRefPubMedPubMedCentral

42.

Weuve J, Ridker PM, Cook NR, Buring JE, Grodstein F. High-sensitivity C-reactive protein and cognitive function in older women. Epidemiology. 2006;17(2):183–9. https://doi.org/10.1097/01.ede.0000198183.60572.c9.CrossRefPubMed

Title: High sensitivity C-reactive protein and glycated hemoglobin levels as dominant predictors of all-cause dementia: a nationwide population-based cohort study
Authors: Yen-Chun Fan
Chia-Chi Chou
Bagas Suryo Bintoro
Kuo-Liong Chien
Chyi-Huey Bai
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Dementia
Dementia
Diabetes
Biomarkers
Published in: Immunity & Ageing / Issue 1/2022
Electronic ISSN: 1742-4933
DOI: https://doi.org/10.1186/s12979-022-00265-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2022

The immunosenescence-related factor DOCK11 is involved in secondary immune responses of B cells

Advanced biological age is associated with improved antibody responses in older high-dose influenza vaccine recipients over four consecutive seasons

Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine

Aging, inflammaging and immunosenescence as risk factors of severe COVID-19

The diseased kidney: aging and senescent immunology

Antibodies in action: the role of humoral immunity in the fight against atherosclerosis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials